
Background: Psoriasis is a chronic skin condition characterized by an overactive immune system, leading to increased keratinocyte proliferation and angiogenesis. Treatment ranges from topical solutions to systemic therapy and lastly, biologics. However, the latter options are typically manufactured with mammalian-derived ingredients. Alpha-gal syndrome (AGS) is an acquired IgE-mediated hypersensitivity reaction to galactose-alpha-1,3-galactose, an enzyme required for digesting carbohydrates in mammalian products. In addition to dietary avoidance of mammalian products, patients with AGS may need to avoid certain medications due to their formulations. Case Presentation: We present a case of a 53-year-old female with a severe alpha-gal allergy evaluated in the Dermatology clinic during a psoriasis flare, where management and treatment were complicated by the patient’s need for mammalian-free derivatives. Discussion: Patients with AGS face many barriers when it comes to managing their autoimmune conditions due to lack of ingredient transparency and mammalian derived vehicles. The development of mammalian-free formulations is urgently needed to improve quality of life in patients with severe autoimmune conditions and concurrent alpha-gal syndrome. Conclusion: This case underscores the importance of identifying effective mammalian-free alternatives while highlighting the need for increased awareness among clinicians and pharmaceutical manufacturers.
Gastric metastases from breast carcinoma are well documented in the literature; however, they may present with extremely subtle clinical, endoscopic, and histologic findings, creating a significant diagnostic challenge. We report a case of metastatic breast carcinoma identified in a routine gastric biopsy obtained to evaluate for Helicobacter pylori infection during esophagogastroduodenoscopy performed as part of the metastatic workup, in a patient with known metastatic disease approximately 10 years after the patient’s initial breast cancer diagnosis. Endoscopic examination showed mildly congested mucosa with thickening of the gastric folds and subtle wall stiffness, but without a discrete mass lesion. Histologic examination revealed only rare discohesive atypical cells infiltrating the lamina propria, which might be difficult to recognize on routine evaluation. Immunohistochemical studies demonstrated positivity for estrogen receptors and GATA3, supporting metastatic breast carcinoma. This case is not presented as a rare occurrence of gastric metastasis, but rather as an important diagnostic pitfall. It illustrates how metastatic breast carcinoma may present as subtle cells in a gastric biopsy that might be overlooked on routine evaluation, even in a patient with known metastatic disease. In patients with a history of breast carcinoma, the presence of even minimal atypical cells in a gastric biopsy should prompt consideration of metastatic disease and appropriate immunohistochemical evaluation. Accurate determination of receptor status, including HER2-low tumors (IHC 2+/FISH-negative), remains important for therapeutic decision-making: HER2-low, hormone receptor-positive breast cancer progressed on endocrine therapy is now an indication for trastuzumab deruxtecan.
Raynaud’s phenomenon is a vasospastic disorder characterized by episodic vasoconstriction of the distal extremities, typically triggered by cold exposure or emotional stress. While primary Raynaud’s is usually symmetric, secondary forms may arise from systemic, vascular, or occupational causes potentially resulting in unilateral or asymmetric presentation. Post-traumatic Raynaud’s phenomenon is rarely reported and is generally limited to transient, distal involvement. In this report, we present a 38-year-old female with Ehlers-Danlos Syndrome and Postural Orthostatic Tachycardia Syndrome (POTS) who developed unilateral Raynaud’s phenomenon following a crush injury to her right foot. She experienced intermittent discoloration and coldness extending to the mid-shin, occurring primarily while standing and worsening in cold environments. Examination during symptomatic episodes revealed the reported color change to the extremity as well as delayed capillary refill, while ankle-brachial indices and computed tomography angiography were normal. Vascular surgery diagnosed secondary Raynaud’s phenomenon, and conservative management was initiated. Consent was obtained from the patient prior to drafting the manuscript and publication. This case highlights an atypical presentation of Raynaud’s phenomenon with unilateral, proximally extending, and position-dependent symptoms following acute trauma. Recognition of this entity is important, as normal vascular imaging does not exclude a functional microvascular disorder. Early diagnosis may prevent unnecessary testing and guide appropriate management, particularly in patients with underlying connective tissue or autonomic conditions.
Introduction The WV Medicaid Drug Utilization Review Board approved a policy limiting prescriptions of Wegovy for cardiovascular risk reduction to cardiologists, vascular surgeons, and neurologists or those in consultation with them. This qualitative study explored specialists’ perspectives on the policy and its perceived implications for patient access to care and clinical practice in rural West Virginia. Methods To assess the perceived impact of this policy, we conducted semi-structured interviews with eight WV-based neurologists, cardiologists, and vascular surgeons between September 2024 and June 2025, while the original prescribing restrictions were in effect. Interview data were analyzed using thematic analysis to identify recurring themes. Results Five themes emerged: Limited education on GLP-1s Limited clinical experience prescribing GLP-1s Concern that the policy will hinder access to Wegovy for eligible patients with cardiovascular risk Concern about increased burden on specialty clinics and disruption of existing workflows Recognition of the value of primary care-specialist collaboration in managing patients who may benefit from GLP-1s Conclusion Specialists reported limited familiarity with GLP-1s and expressed concerns about the policy's potential effects on patient access to care and specialty clinic operations. These findings underscore the importance of engaging stakeholders in policy development to support patient access to care and improve health outcomes.
Introduction: There is literature in the obstetric population that suggests any degree of hypertension (blood pressures greater than or equal to 120 systolic or 80 diastolic) can lead to adverse maternal and fetal outcomes. We sought to determine if pregnant patients in our Appalachian population with elevated blood pressure or stage 1 hypertension have an increased risk of gestational hypertension and preeclampsia. Methods: A retrospective chart review was performed on patients who received obstetric care with the Marshall University OB/GYN department and delivered at Cabell Huntington Hospital. Delivery outcomes were obtained for 233 deliveries from March 30, 2020 to September 30, 2020 in patients who did not meet obstetric criteria for chronic hypertension at the initial prenatal visit in the first trimester. Patients were divided into three groups: normotensive with blood pressurediastolic, elevated blood pressure of 120-129 systolic anddiastolic, or stage 1 hypertension of 130-139 systolic or 80-89 diastolic. Maternal demographics and pregnancy outcomes were compared. Results:There were 78 normotensive patients, 61 patients with elevated blood pressure, and 94 patients with stage 1 hypertension. There was a significant difference in gestational age at delivery, with stage I hypertension having significantly lower gestational age compared to controls and elevated blood pressure status (p value Conclusion: Stage 1 hypertension in the first trimester increases the risk of gestational hypertension, preeclampsia, and early delivery in Appalachian gravidas. Pregnant patients who do not meet obstetric criteria for chronic hypertension but have elevated blood pressure are at risk for adverse outcomes. Strategies directed at individuals with elevated blood pressure are needed to improve both maternal and fetal outcomes.